However, combining vascular endothelial growth factor (VEGF) inhibitors (e.g. bevacizumab) with PD-L1 inhibitors like atezolizumab may reverse VEGF-mediated immunosuppression, support dendritic cell maturation, and promote T-cell infiltration into the tumor, as supported by published preclinical evidence.12 The gene discussed is VEGFA; the disease is neoplasm.